Last reviewed · How we verify
acetaminophen extended release caplets
Acetaminophen extended release caplets, marketed by Johnson & Johnson Consumer and Personal Products Worldwide, holds a significant position in the pain management market. The key composition patent is set to expire in 2028, providing a strong competitive advantage until then. The primary risk is the potential increase in generic competition following the patent expiry.
At a glance
| Generic name | acetaminophen extended release caplets |
|---|---|
| Sponsor | Johnson & Johnson Consumer and Personal Products Worldwide |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in Treating Muscle Aches and Soreness That Occur After a Marathon Race (PHASE4)
- An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee. (PHASE3)
- A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee (PHASE3)
- An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness. (PHASE4)
- An Effectiveness and Safety Study of Two Doses of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee (PHASE3)
- A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fed Condition (NA)
- A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fasting Condition (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |